Recombinate
NDC Package 0944-2831-15
Package Information
Recombinate is the use of RECOMBINATE [Antihemophilic Factor (Recombinant)] is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes.2 RECOMBINATE is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia).RECOMBINATE can be of therapeutic value in patients with acquired Factor VIII inhibitors not exceeding 10 Bethesda Units per mL.3 In clinical studies with RECOMBINATE, patients with inhibitors who were entered into the previously treated patient trial and those previously untreated children who have developed inhibitor activity on study, showed clinical hemostatic response when the titer of inhibitor was less than 10 Bethesda Units per mL. Marketed by Baxalta Us Inc., this product is identified by NDC 0944-2831 and is authorized under FDA application BLA103375.
Identification & Billing
- RxCUI: 1719222 - antihemophilic factor, human recombinant 1 UNT Injection
- RxCUI: 1719222 - factor VIII, human recombinant 1 UNT Injection
- RxCUI: 1719243 - RECOMBINATE 1 UNT Injection
- RxCUI: 1719243 - antihemophilic factor, human recombinant 1 UNT Injection [Recombinate]
- RxCUI: 1719243 - Recombinate 1 UNT Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0944 - Baxalta Us Inc.
- 0944-2831 - Recombinate
- 0944-2831-15 - 1 KIT in 1 CARTON * 1 VIAL, GLASS in 1 CARTON / 10 mL in 1 VIAL, GLASS * 1 VIAL, GLASS in 1 CARTON / 10 mL in 1 VIAL, GLASS
- 0944-2831 - Recombinate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0944-2831-15 identifies a specific commercial package of 1 kit in 1 carton * 1 vial, glass in 1 carton / 10 ml in 1 vial, glass * 1 vial, glass in 1 carton / 10 ml in 1 vial, glass of Recombinate, labeled by Baxalta Us Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Baxalta Us Inc. on February 08, 2010. The current certification is valid through August 14, 2010.
How is this Baxalta Us Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00944283115. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.